CN102836320A - 治疗快速型心律失常的中药丸 - Google Patents
治疗快速型心律失常的中药丸 Download PDFInfo
- Publication number
- CN102836320A CN102836320A CN2012103762243A CN201210376224A CN102836320A CN 102836320 A CN102836320 A CN 102836320A CN 2012103762243 A CN2012103762243 A CN 2012103762243A CN 201210376224 A CN201210376224 A CN 201210376224A CN 102836320 A CN102836320 A CN 102836320A
- Authority
- CN
- China
- Prior art keywords
- rhizoma
- radix
- pinelliae preparatum
- poria
- rhizoma pinelliae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000001871 Tachycardia Diseases 0.000 title claims abstract description 30
- 206010049447 Tachyarrhythmia Diseases 0.000 title claims abstract description 28
- 239000006187 pill Substances 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 23
- 239000000843 powder Substances 0.000 claims abstract description 20
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 19
- 239000007788 liquid Substances 0.000 claims abstract description 19
- 239000000706 filtrate Substances 0.000 claims abstract description 7
- 241000237903 Hirudo Species 0.000 claims description 18
- 210000000582 semen Anatomy 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 14
- 230000008569 process Effects 0.000 claims description 12
- 206010003119 arrhythmia Diseases 0.000 claims description 8
- 230000006793 arrhythmia Effects 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 238000012545 processing Methods 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 26
- 239000002994 raw material Substances 0.000 abstract description 3
- 241000304531 Allium macrostemon Species 0.000 abstract 2
- 241000545744 Hirudinea Species 0.000 abstract 2
- 244000088415 Raphanus sativus Species 0.000 abstract 2
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 abstract 2
- 235000017276 Salvia Nutrition 0.000 abstract 2
- 240000007164 Salvia officinalis Species 0.000 abstract 2
- 235000008326 Trichosanthes anguina Nutrition 0.000 abstract 2
- 244000078912 Trichosanthes cucumerina Species 0.000 abstract 2
- 235000013399 edible fruits Nutrition 0.000 abstract 2
- 230000005476 size effect Effects 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 15
- 206010062717 Increased upper airway secretion Diseases 0.000 description 12
- 208000026435 phlegm Diseases 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 10
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000017531 blood circulation Effects 0.000 description 6
- 230000001914 calming effect Effects 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 230000000747 cardiac effect Effects 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- YGULWPYYGQCFMP-CEAXSRTFSA-N Metoprolol tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 YGULWPYYGQCFMP-CEAXSRTFSA-N 0.000 description 4
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 4
- 238000002555 auscultation Methods 0.000 description 4
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 description 3
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 description 3
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 2
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- FEFAIBOZOKSLJR-UHFFFAOYSA-N Miltirone Chemical compound C1CCC(C)(C)C=2C1=C1C(=O)C(=O)C(C(C)C)=CC1=CC=2 FEFAIBOZOKSLJR-UHFFFAOYSA-N 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 208000000418 Premature Cardiac Complexes Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- FYRHTIWFKXZWAD-UHFFFAOYSA-N Sarisan Chemical compound C1=C(CC=C)C(OC)=CC2=C1OCO2 FYRHTIWFKXZWAD-UHFFFAOYSA-N 0.000 description 2
- 206010000059 abdominal discomfort Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000007373 indentation Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 2
- 229960002237 metoprolol Drugs 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 206010047302 ventricular tachycardia Diseases 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 description 1
- PTTPXKJBFFKCEK-UHFFFAOYSA-N 2-Methyl-4-heptanone Chemical compound CC(C)CC(=O)CC(C)C PTTPXKJBFFKCEK-UHFFFAOYSA-N 0.000 description 1
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 208000003734 Supraventricular Tachycardia Diseases 0.000 description 1
- 206010065342 Supraventricular tachyarrhythmia Diseases 0.000 description 1
- 229930183118 Tanshinone Natural products 0.000 description 1
- 206010065341 Ventricular tachyarrhythmia Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229940039750 aconitine Drugs 0.000 description 1
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000001964 calcium overload Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 230000005831 heart abnormality Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940002661 lipitor Drugs 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229960003371 protocatechualdehyde Drugs 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000004124 rheumatic heart disease Diseases 0.000 description 1
- PRYXPGFZVGZNBL-ADLFWFRXSA-N salviol Chemical compound CC(C)c1cc2CC[C@H]3C(C)(C)C[C@H](O)C[C@]3(C)c2cc1O PRYXPGFZVGZNBL-ADLFWFRXSA-N 0.000 description 1
- AJSGWTLZEUBGFV-UHFFFAOYSA-N salviol Natural products CC(C)c1cc2CCC3C(CC(O)CC3(C)C)c2cc1O AJSGWTLZEUBGFV-UHFFFAOYSA-N 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 229940093252 sorbitrate Drugs 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 229960000887 spectinomycin hydrochloride Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229930189533 tanshinol Natural products 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201210376224 CN102836320B (zh) | 2012-10-08 | 2012-10-08 | 治疗快速型心律失常的中药丸 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201210376224 CN102836320B (zh) | 2012-10-08 | 2012-10-08 | 治疗快速型心律失常的中药丸 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102836320A true CN102836320A (zh) | 2012-12-26 |
CN102836320B CN102836320B (zh) | 2013-09-04 |
Family
ID=47364223
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201210376224 Active CN102836320B (zh) | 2012-10-08 | 2012-10-08 | 治疗快速型心律失常的中药丸 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102836320B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105641621A (zh) * | 2016-02-19 | 2016-06-08 | 浙江省中医院 | 痰瘀同治颗粒及其服用方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1319412A (zh) * | 2001-01-16 | 2001-10-31 | 刘红 | 用于治疗快速心律失常的药物 |
CN1408389A (zh) * | 2001-09-28 | 2003-04-09 | 杨锡铭 | 一种用于治疗心律失常的中药及其制法 |
CN1931354A (zh) * | 2005-09-16 | 2007-03-21 | 高松寿 | 一种治疗心律失常的中药制剂及其制备方法 |
-
2012
- 2012-10-08 CN CN 201210376224 patent/CN102836320B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1319412A (zh) * | 2001-01-16 | 2001-10-31 | 刘红 | 用于治疗快速心律失常的药物 |
CN1408389A (zh) * | 2001-09-28 | 2003-04-09 | 杨锡铭 | 一种用于治疗心律失常的中药及其制法 |
CN1931354A (zh) * | 2005-09-16 | 2007-03-21 | 高松寿 | 一种治疗心律失常的中药制剂及其制备方法 |
Non-Patent Citations (2)
Title |
---|
徐江雁等: "国家级名老中医治疗冠心病经验", 《中医研究》, vol. 23, no. 4, 30 April 2010 (2010-04-30), pages 54 - 59 * |
赵玉荣等: "心律失常的中医药治疗概况", 《河南中医药学刊》, vol. 13, no. 2, 31 December 1998 (1998-12-31), pages 63 - 65 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105641621A (zh) * | 2016-02-19 | 2016-06-08 | 浙江省中医院 | 痰瘀同治颗粒及其服用方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102836320B (zh) | 2013-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100382839C (zh) | 一种治疗冠心病的中药组合物 | |
CN100435831C (zh) | 治疗高血压、高血脂、肥胖症及更年期综合症的制剂及其制备方法 | |
CN101708281A (zh) | 一种养心安神的中药制剂及其制备方法 | |
CN102283940B (zh) | 一种治疗心悸的中药制剂 | |
CN104922611B (zh) | 一种治疗心律失常的中药组合物及其制备方法 | |
CN103393749A (zh) | 一种防治缺血性心脑血管疾病的中药 | |
CN100455313C (zh) | 一种治疗心脑血管疾病的中药 | |
CN102836320B (zh) | 治疗快速型心律失常的中药丸 | |
CN105456689A (zh) | 一种治疗糖尿病的中药组合物及其制备方法和用途 | |
CN104324134B (zh) | 一种改善微循环的中药组合物及其制备方法 | |
CN112316051B (zh) | 养血化痰中药组合物及其中药制剂、制备方法和应用 | |
CN101254266B (zh) | 一种治疗心脑血管疾病的药物 | |
CN100574800C (zh) | 一种治疗心脑动脉粥样硬化病的中成药及其制作方法 | |
CN103230457A (zh) | 一种治疗病毒性心肌炎的中药组合物及其制备方法与用途 | |
CN104306649B (zh) | 一种治疗带状疱疹的药剂 | |
CN111529659A (zh) | 治疗缓慢性心律失常的中药组合物及其制备方法和应用 | |
CN102204956B (zh) | 一种用于中风恢复期的中药组合物及其制备方法 | |
CN110339323A (zh) | 一种治疗心动过缓的中药组合物及其制备方法和应用 | |
CN103349709B (zh) | 一种益气养阴、滋补肝肾的中药制剂 | |
CN112294901B (zh) | 治疗室上性心律失常的中药组合物及其制备方法和应用 | |
CN102205049B (zh) | 一种治疗早搏的药物组合物 | |
CN108310207B (zh) | 一种治疗心力衰竭的药物组合物及其制备方法 | |
CN101507777B (zh) | 治疗冠心病的药物组合物及其制备方法 | |
CN105770520A (zh) | 一种用于治疗冠心病的药物制剂及其用途 | |
CN104338087B (zh) | 一种治疗冠心病的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 450018 Jinshui East Road, Zheng Dong New District, Zhengzhou, Henan, 156 Patentee after: HENAN University OF CHINESE MEDICINE Address before: 450008 No. 1 Jinshui Road, Jinshui District, Henan, Zhengzhou Patentee before: HENAN University OF Chinese Medicine |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231220 Address after: No. 20, Unit 1, East, Building 10, Employee Residential Building, Longzihu Campus, Henan University of Traditional Chinese Medicine, Mingli Road, Zhengdong New District, Zhengzhou City, Henan Province, 450018 Patentee after: Henan Huayi Yingmei Medical Technology Co.,Ltd. Address before: 450018 Jinshui East Road, Zheng Dong New District, Zhengzhou, Henan, 156 Patentee before: HENAN University OF CHINESE MEDICINE |